Loading clinical trials...
Loading clinical trials...
Local and Systemic Safety and Tolerability of Ascending Doses of TOP-N53, a Nitric Oxide (NO)-Releasing Phosphodiesterase-5 (PDE5) Inhibitor, Administered Topically, on Wounds in Patients With Digital Ulcers (DU) in Systemic Sclerosis (SSc) in an Open-label, Vehicle-controlled, Phase 2a, Multi-center Clinical Trial
Conditions
Interventions
TOP-N53
Sildenafil
+1 more
Locations
5
France
Centre Hospitalier Universitaire de Bordeaux, Service de Rhumatologie
Bordeaux, France
CHU Grenoble Alpes
La Tronche, France
CHRU Lille, Hôpital Claude Huriez, Rue Michel Polonosvski
Lille, France
AP-HP Hôpital Cochin
Paris, France
Reha Rheinfelden, Salinenstrasse 98
Rheinfelden, Canton of Aargau, Switzerland
Start Date
February 4, 2025
Primary Completion Date
March 31, 2026
Completion Date
March 31, 2026
Last Updated
January 9, 2026
Lead Sponsor
Topadur Pharma AG
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions